217P Switching cyclin-dependent kinase inhibitors (CDK4/6i) in patients with hormone receptor-positive (HR+)/human epidermal growth factor-negative (HER2-) advanced breast cancer (ABC) who experienced unacceptable toxicityC. Benvenuti, Rita De Sanctis, Flavia Jacobs et al.|ESMO Open|2024Cited by 2